| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC25A6 |
| Uniprot No | P12236 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 232-272aa |
| 氨基酸序列 | DTVRRRMMMQSGRKGADIMYTGTVDCWRKIFRDEGGKAFFK |
| 预测分子量 | 20.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC25A6重组蛋白的示例参考文献(注：以下为模拟内容，建议通过学术数据库查询真实文献)：
---
1. **标题**：*Recombinant expression and functional analysis of human SLC25A6 in yeast mitochondria*
**作者**：G. Ruprecht et al.
**摘要**：研究通过酵母表达系统重组表达了人源SLC25A6蛋白，验证其在线粒体中的ADP/ATP转运活性，并发现其功能受膜电位调控。
2. **标题**：*Crystal structure of the SLC25A6-ATP complex reveals substrate recognition mechanism*
**作者**：K. Tanaka et al.
**摘要**：报道了重组SLC25A6蛋白的晶体结构，揭示了ATP结合的关键氨基酸残基，为理解转运机制提供结构基础。
3. **标题**：*SLC25A6 recombinant protein rescues mitochondrial dysfunction in cellular models*
**作者**：L. Martínez et al.
**摘要**：利用重组SLC25A6蛋白在细胞模型中恢复线粒体膜电位和能量代谢，证明其在治疗线粒体疾病中的潜在应用。
4. **标题**：*Comparative kinetics of recombinant SLC25A6 isoforms in liposome-based transport assays*
**作者**：S. Park et al.
**摘要**：通过脂质体包裹重组SLC25A6异构体，比较不同剪接变体的ADP/ATP转运效率，发现组织特异性功能差异。
---
建议通过PubMed或Google Scholar搜索关键词“SLC25A6 recombinant protein”或“SLC25A6 expression/purification”获取真实文献。
SLC25A6. also known as adenine nucleotide translocase 1 (ANT1), is a member of the solute carrier family 25 (SLC25), which comprises mitochondrial carrier proteins responsible for transporting metabolites, nucleotides, and cofactors across the mitochondrial inner membrane. As a key component of cellular energy metabolism, SLC25A6 facilitates the exchange of ADP and ATP between the mitochondrial matrix and cytosol, a critical process for maintaining ATP homeostasis and supporting cellular functions. It is predominantly expressed in tissues with high energy demands, such as the heart, skeletal muscle, and liver.
The recombinant SLC25A6 protein is engineered through molecular cloning and heterologous expression systems (e.g., E. coli or mammalian cells) to study its structural and functional properties. This approach enables researchers to investigate its role in mitochondrial physiology, including its involvement in oxidative phosphorylation, apoptosis regulation, and potential links to diseases. Structural studies reveal that SLC25A6 forms a homodimer with six transmembrane helices, featuring conserved motifs critical for substrate binding and transport.
Dysregulation of SLC25A6 has been associated with mitochondrial disorders, cancer, and metabolic syndromes. Recombinant versions are widely used in biochemical assays to screen modulators or analyze mutations affecting transport activity. Additionally, recombinant SLC25A6 serves as a tool to explore its interaction with ligands like the pro-apoptotic protein Bax or the adenine nucleotide translocase inhibitor carboxyatractyloside.
The production of recombinant SLC25A6 often faces challenges such as maintaining proper folding and membrane integration due to its hydrophobic nature. Advanced expression systems and purification strategies (e.g., affinity chromatography, detergent solubilization) are employed to obtain functional protein for in vitro studies. Ongoing research aims to elucidate its regulatory mechanisms and therapeutic potential in mitochondrial dysfunction-related diseases.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
